Form 4: Teva Pharmaceutical Director Roberto Mignone Reports Equity Transactions and New RSU Grant

Teva Pharmaceutical Industries Ltd. Director Roberto Mignone reported the vesting and acquisition of 9,632 ordinary shares from restricted share units, alongside a new grant of 14,492 restricted share units.

Summary

• Roberto Mignone, a Director of Teva Pharmaceutical Industries Ltd. (TEVA), filed a Form 4 detailing changes in his beneficial ownership.
• On June 6, 2025, Mr. Mignone acquired 9,632 ordinary shares of Teva Pharmaceutical Industries Ltd. through the vesting of previously granted restricted share units (RSUs).
• Following this transaction, Mr. Mignone directly beneficially owns 105,315 ordinary shares.
• Additionally, Mr. Mignone indirectly beneficially owns 695,000 ordinary shares held by Swiftcurrent Master Fund, Ltd., where Bridger Management, LLC, managed by Mr. Mignone, serves as the investment adviser. Mr. Mignone disclaims beneficial ownership except to the extent of his pecuniary interest.
• On June 5, 2025, Mr. Mignone was granted 14,492 new restricted share units, which are scheduled to vest on June 5, 2026.
• Each restricted share unit represents a contingent right to receive one ordinary share or its cash equivalent at settlement, at the option of the Human Resources and Compensation Committee.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director is increasing their direct share ownership (through RSU vesting) and receiving new equity compensation, which generally aligns their interests with shareholders. These are routine compensation-related transactions.

Positives

• The acquisition of 9,632 ordinary shares by a director, even through RSU vesting, increases insider ownership, which can align management interests with shareholders.
• The grant of 14,492 new restricted share units indicates continued equity-based compensation for the director, further aligning long-term interests.

Risks

• Mr. Mignone disclaims beneficial ownership of the 695,000 ordinary shares held by Swiftcurrent Master Fund, Ltd., except to the extent of his indirect pecuniary interest, which may introduce complexity in assessing his full economic exposure to Teva's stock performance.

Future Outlook

The newly granted 14,492 restricted share units are scheduled to vest on June 5, 2026, indicating future share acquisition for the director as part of his compensation plan.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions and does not provide specific insights into broader pharmaceutical industry trends or Teva's competitive positioning.

Related Party Transactions

• Roberto Mignone indirectly beneficially owns 695,000 ordinary shares held by Swiftcurrent Master Fund, Ltd., where Bridger Management, LLC, managed by Mr. Mignone, serves as the investment adviser. Mr. Mignone disclaims beneficial ownership of these shares except to the extent of his indirect pecuniary interest.

Stakeholder Impact

• Shareholders may view the director's increased direct ownership and ongoing equity compensation as a positive sign of alignment between management and shareholder interests.

Next Steps

• The 14,492 restricted share units granted on June 5, 2025, are expected to vest on June 5, 2026, at which point Mr. Mignone would acquire additional ordinary shares.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, SEC filing, insider trading, stock ownership, director, restricted stock units, RSU, equity compensation, pharmaceuticals